NIH Plans to Disband RAC

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 7
Volume 5
Issue 7

Bethesda , Md--NIH director Harold Varmus has announced plants to disband the Recombinant DNA Advisory Committee (RAC). The committee was formed in 1975 as a panel of 24 scientists, ethicists, and others at NIH dedicated to holding those in the field of biogenetics accountable to the public.

Bethesda , Md--NIH director Harold Varmus has announced plantsto disband the Recombinant DNA Advisory Committee (RAC). The committeewas formed in 1975 as a panel of 24 scientists, ethicists, andothers at NIH dedicated to holding those in the field of biogeneticsaccountable to the public.

The RAC created the first safety guidelines for genetically engineeringmicrobes, instituted a formal review system for studies involvinginsertion of new genes into humans, and, in 1990, gave the firstapproval of a human gene therapy experiment. RAC approval wasrequired before the FDA would consider any gene therapy proposal.

Now, Dr. Varmus believes the RAC is no longer necessary, as theFDA can handle all new proposals with the help of ad hoc committeesconvened as needed.

Recent Videos
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
2 experts are featured in this series.
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content